secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268072
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M
--------------------------------------------------------------------------------

- Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).
- End-of-Phase 2 FDA meeting by end 2025; two Phase 3 FOS trials to start Q3 2026.
- Q3 net loss $26.9M (vs $17.5M YoY); R&D $22.3M, G&A $7.7M.
- Cash, equivalents, and ST investments $513.0M; includes $269.4M net from September public offering.
- Bipolar mania Phase 2 enrolling; topline expected H1 2027. DPNP trial on FDA clinical hold; update Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/0001193125-25-268072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/rapp-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer